MedTrace Logo

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

NCT05462353 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2025-01-08

No results posted yet for this study

Summary

This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).

Conditions

  • Non-alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis

Interventions

DRUG

2mg of ASC41

ASC41 tablet administered orally once daily.

DRUG

4mg of ASC41 (2 tablets of 2 mg ASC41)

ASC41 tablets administered orally once daily.

DRUG

Placebo

Placebo tablets administered orally once daily.

Sponsors & Collaborators

  • Gannex Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2025-05-10
Completion
2025-06-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462353 on ClinicalTrials.gov